Myriad Genetics shares are trading lower after the company announced that it discontinued the second part of its study due to the disparities between the GeneSight Group and control group.
Portfolio Pulse from Benzinga Newsdesk
Myriad Genetics shares fell after the company halted the second part of its study due to disparities between the GeneSight Group and the control group.
September 04, 2024 | 3:51 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Myriad Genetics shares declined following the announcement of halting the second part of its study due to disparities between the GeneSight Group and control group.
The decision to halt the study indicates potential issues with the GeneSight product, which could affect investor confidence and future revenue expectations, leading to a short-term negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100